LONDON and CAMBRIDGE, MA--(Marketwire - December 16, 2008) - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the British Journal of Cancer has today published the results of a randomised phase II trial of ASA404 in non-small cell lung cancer (NSCLC). Positive data from this trial supported the progress of ASA404 into phase III development. ASA404 is a Tumour-Vascular Disrupting Agent (Tumour-VDA) that attacks tumours by selectively destroying the tumour blood vessels on which they depend to survive and grow.
